drugset / Trial / NCT00116831

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

NCT00116831

Phase 3 Completed 672 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.

Timeline

Start
2005-01
Primary completion
2008-08
Completion
2008-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glipizide Small molecule Oral
Subject Rosiglitazone Small molecule Oral

Indications